Coronary Artery Disease Clinical Trials 2023

What are the top hospitals conducting coronary artery disease research?

Coronary artery disease is a prevalent and serious condition that affects millions of people worldwide. In the quest to find innovative treatments and interventions, top hospitals are leading the way with their extensive clinical trial programs. Massachusetts General Hospital in Boston stands out as a pioneer, currently running 11 active trials for coronary artery disease while boasting an impressive history of 50 completed studies since recording their first trial in 2002. Meanwhile, Emory University Hospital in Atlanta has made significant contributions to this field with seven ongoing trials and a total of 33 conducted trials since their inception into coronary artery disease research also in 2002.

In Canada's capital city, Ottawa, the University of Ottawa Heart Institute takes part in advancing knowledge about heart health by conducting six active clinical trials for coronary artery disease along with fifty prior investigations spanning from when they initiated their trailblazing work back in 2000. On the west coast, Cedars-Sinai Medical Center located in Los Angeles has been committed to combating this cardiovascular condition through five ongoing trials and twenty-seven previous explorations after beginning its journey towards understanding it during early phase only just one year later than our founding institution- all starting at around 2001.

Furthermore adding itself among these esteemed institutions comes another pillar: The prestigious University of Pittsburgh Medical Center situated right within Pennsylvania's "Steel City". UPMC endeavors towards improving lives afflicted by coronary artery diseases via actively pursuing five current clinical examinations alongside experience garnered through twenty-three earlier endeavours which began gaining momentum slightly late; having started off merely two years away from now -back then during1994.

These accomplished hospitals demonstrate not only dedication but also remarkable progress achieved thus far on our collective fight against coronary artery disease. Their relentless pursuit of new treatments brings hope to countless individuals affected by this condition globally. As we continue supporting such groundbreaking research, we move closer to discovering more effective strategies for prevention, diagnosis, and treatment -- ultimately saving lives and improving the quality of life for those battling this widespread ailment.

Which are the best cities for coronary artery disease clinical trials?

When it comes to clinical trials for coronary artery disease, several cities are leading the way in research and development. New york City boasts 37 active trials focusing on treatments like Impella CP® and multiple arterial grafting. Boston, Massachusetts follows closely behind with 26 ongoing studies exploring interventions such as IV acetaminophen and Microport Firehawk stent. Atlanta, Georgia also plays a significant role in research with 19 active trials investigating medical/behavioral therapy and orbital atherectomy. Additionally, Gainesville, Florida is conducting 19 trials targeting ACE-I (lisinopril) or ARB (losartan) treatment options alongside other innovations. Lastly, Jacksonville, Florida conducts 14 clinical trials examining interventions like Evolocumab and potent P2Y12 monotherapy. These cities serve as hubs for cutting-edge research that strive to improve the outcomes of individuals affected by coronary artery disease.

Which are the top treatments for coronary artery disease being explored in clinical trials?

The quest for better treatments for coronary artery disease is ongoing, with two promising options currently in clinical trials. Ticagrelor has caught the attention of researchers with its potential benefits, participating in two active trials and making a total of nine all-time trials dedicated to coronary artery disease since its introduction in 2010. Another contender on the horizon is the CardioGard Embolic Protection Cannula, a novel device being investigated in one active trial as well as being listed once previously in 2023. These advancements provide hope for improved outcomes and quality of life for individuals affected by this prevalent cardiovascular condition.

What are the most recent clinical trials for coronary artery disease?

Recent clinical trials have provided valuable insights into the treatment of coronary artery disease, offering potential advancements in patient care. A Phase 4 trial investigating the use of colchicine has shown promise in managing this condition. Another Phase 4 trial focuses on interventions for coronary artery disease, aiming to improve outcomes and quality of life for patients. Additionally, a Phase 1 study explores the effectiveness of rectus sheath block with PIFB as an experimental approach to treating coronary artery disease. Further research is being conducted on dapagliflozin and potent P2Y12 monotherapy as potential therapies for this cardiovascular condition. These studies offer hope for improved treatments and enhanced management strategies moving forward.

What coronary artery disease clinical trials were recently completed?

Recently, several clinical trials have been completed to advance our understanding and treatment of coronary artery disease. Notably, GE Healthcare successfully concluded a trial in January 2022 examining the potential of Flurpiridaz (18F) Injection. In February 2021, the University of Florida wrapped up their investigation into Cangrelor therapy. Additionally, XyloCor Therapeutics' AdVEGFXC1 study reached completion in January 2020. These comprehensive trials contribute valuable insights towards combating this prevalent cardiovascular condition and offer hope for patients worldwide.